AHA Urges HHS to Take Action Against Drug Manufacturers for Limiting the Distribution of 340B Drugs

July 30, 2020

AHA expresses concern regarding recent action taken by three major drug manufacturers – Eli Lilly and Co., Merck and Sanofi – to limit the distribution of certain 340B drugs to our hospital members. Eli Lilly has filed its notice to limit the distribution of certain 340B drugs with the Office of Pharmacy Affairs within the Health Resources and Services Administration (HRSA). Merck and Sanofi have directly communicated with our 340B hospital members requesting detailed information about any 340B drugs distributed through the hospital’s contract pharmacy arrangements. The Merck and Sanofi communications explain the purpose of the request is to investigate possible duplicate discounts provided to state Medicaid programs.  We urge HRSA to address these abuses by Merck, Eli Lilly and Sanofi and request they cease this activity and work to ensure that 340B drugs are available and accessible to communities and vulnerable populations. 

Related Resources

Special Bulletin
Download the AHA Special Bulletin: CMS Issues Hospital Outpatient/ASC Proposed Rule, Including Modifications to Price Transparency Rule
Special Bulletin
President Biden today signed an executive order (EO) establishing a “whole-of-government” effort to promote competition in the American economy. The EO…
AHA Center for Health Innovation Market Scan
As patients and politicians continue searching for remedies to soaring insulin prices for diabetes patients, Walmart recently launched the first private-label…
Advancing Health Podcast
Columbus, Ohio-based Mount Carmel Health System goes beyond the walls of its hospital to serve its community and patients through programs such as Street…
Amy Bricker President Express Scripts PBM 1 Express Way Saint Louis, MO 63121 Dear Ms. Bricker:
Action Alert
Please contact your members of Congress and urge them to support legislation that will provide certainty to hospitals participating in the 340B Drug Pricing…